Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Zhu, You‐cai; Wang, Wenxian; Xu, C.; Tan, Qi; Li, Jianying; Zhuang, W.; Song, Zhengbo; Du, Ke; Chen, Gang; Lv, Tangfeng; Song, Yong

doi:10.21037/jtd.2018.04.162

Cited by 14 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case reported a male patient with lung adenocarcinoma and an EGFR-KDD mutation detected with NGS, who had a preferable anti-tumor response to afatinib, a second-generation EGFR-TKI (6). Zhu et al (9) reported the first case involving the presence of oncogenic EGFR-KDD in China, who had stable disease to treatment with an EGFR-TKI icotinib. Another case report of a prolonged multi-year response to gefitinib and then erlotinib has been described for advanced EGFR-KDD mutated lung adenocarcinoma (8).…”

Section: Discussionmentioning

confidence: 99%

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

Chen¹,

Li²,

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Introduction: Oncogenic mutations in the epidermal growth factor receptor (EGFR) occur frequently in patients with lung cancer. These mutations may serve as critical predictive biomarkers in patients with non-small cell lung cancer (NSCLC). Among them, EGFR exon 18-25 kinase domain duplication (EGFR-KDD) mutations have been identified as a novel EGFR gene subtype in NSCLC. Case Presentation: We reported a rare case of a 59-year-old male diagnosed with adenocarcinoma. A biopsy revealed an EGFR-KDD identified by the next generation sequencing (NGS). Effective treatment outcome has been observed after administration with afatinib. Conclusion: This case highlights that comprehensive NGS technique is valuable in detecting novel genetic mutations in tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

Chen¹,

Li²,

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…KDD occurring in exon 18–25 is the most common form, as the unusual events in exon 17–25 and exon 14–26 were also reported . Limited data have shown that NSCLCs with EGRF‐KDD displayed sensitivity to several EGRF tyrosine kinase inhibitors (TKIs), but the efficiency varied, with a total of 6 out of 11 cases achieving partial response as reported . In vitro study demonstrated that erlotinib, afatinib and osimertinib preserved the antitumor response by inhibiting EGFR‐KDD tyrosine phosphorylation in a dose‐dependent manner .…”

mentioning

confidence: 90%

“…In vitro study demonstrated that erlotinib, afatinib and osimertinib preserved the antitumor response by inhibiting EGFR‐KDD tyrosine phosphorylation in a dose‐dependent manner . The reported progression‐free survival (PFS) of EGFR‐KDD to TKIs from literature was ~6 months . Interestingly, the duration of response to first‐generation TKIs varied greatly.…”

mentioning

confidence: 99%

“…1 Limited data have shown that NSCLCs with EGRF-KDD displayed sensitivity to several EGRF tyrosine kinase inhibitors (TKIs), but the efficiency varied, with a total of 6 out of 11 cases achieving partial response as reported. [1][2][3][4][5][6][7] In vitro study demonstrated that erlotinib, afatinib and osimertinib preserved the antitumor response by inhibiting EGFR-KDD tyrosine phosphorylation in a dose-dependent manner. 2 The reported progression-free survival (PFS) of EGFR-KDD to TKIs from literature was 6 months.…”

mentioning

confidence: 99%

“…2 The reported progression-free survival (PFS) of EGFR-KDD to TKIs from literature was 6 months. [1][2][3][4] Interestingly, the duration of response to firstgeneration TKIs varied greatly. The best responses were achieved on gefitinib with a 6-year PFS.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Osimertinib confers potent binding affinity to EGFR kinase domain duplication

Jin

Zhou

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Tyrosine kinase‐altered spindle cell neoplasms with EGFR internal tandem duplications

Kao

Pinto

Trobaugh‐Lotrario

et al. 2022

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

In this study, we present two extra‐renal pediatric spindle cell neoplasms with epidermal growth factor receptor (EGFR) internal tandem duplications (ITD). Histologically, these tumors demonstrated the same histologic features seen in other tyrosine kinase‐altered spindle cell neoplasms, with one case showing abundant adipose tissue with cellular fibrous septae resembling lipofibromatosis and the other case showing fascicles of spindled cells resembling infantile fibrosarcoma. There was variable expression of CD34, S100, and SMA, and all cases were negative for panTRK. This case series adds to our molecular understanding of the spectrum of tyrosine kinase‐altered spindle cell neoplasms and represents the first reported examples of EGFR ITDs in extra‐renal tumors. The presence of EGFR alterations in the absence of gene fusions represents a potential therapeutic target and necessitates a broader testing panel for this group of tumors.

show abstract

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Cited by 14 publications

References 16 publications

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

Osimertinib confers potent binding affinity to EGFR kinase domain duplication

Tyrosine kinase‐altered spindle cell neoplasms with EGFR internal tandem duplications

Contact Info

Product

Resources

About